In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Abbott gets rights to Reata's Phase II bardoxolone

Executive Summary

Reata Pharmaceuticals Inc. (developing oral anti-inflammatories) has licensed Abbott Laboratories Inc. exclusive rights outside the US and some Asian countries to develop and commercialize bardoxolone (RTA402), which is in late Phase II trials for chronic kidney disease (CKD).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Equity

Related Companies

Advertisement
UsernamePublicRestriction

Register